---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-094911"
form_type: "8-K"
ticker: "ACOG"
cik: "0001655923"
company_name: "Alpha Cognition Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:56:18.996039+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alpha Cognition prices $35M oversubscribed public offering at $6.25/share

## Summary
- Gross proceeds of ~$35M from 5.6M shares (incl. pre-funded warrants) at $6.25 per share.
- Offering was oversubscribed; led by premier healthcare-dedicated investor and large existing shareholders.
- Expected to close Oct 2, 2025; underwriter has 30-day option to purchase up to 840K additional shares.
- Net proceeds to accelerate commercial launch of ZUNVEYL (Benzgalantamine) for Alzheimer's disease.
- Company expects total cash position of approximately $70 million following the closing.

## SEC filing metadata
- accession: 0001213900-25-094911
- form_type: 8-K
- ticker: ACOG
- cik: 0001655923
- company_name: Alpha Cognition Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655923/000121390025094911/0001213900-25-094911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655923/000121390025094911/ea0259660-8k_alpha.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-094911
- JSON: https://secwatch.observer/filing/0001213900-25-094911.json
- Plain text: https://secwatch.observer/filing/0001213900-25-094911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.